Stock Options Grant - The company granted a total of 2,251,500 stock options to senior management and employees on October 5, 2022, under the post-IPO stock option plan[4]. - The exercise price for the stock options is set at HKD 1.728 per share, which is the higher of the closing price on the grant date (HKD 1.720) and the average closing price over the five trading days prior to the grant date[6]. - The total number of stock options granted represents approximately 9.54% of the company's issued share capital as of March 30, 2022, with a potential total of 48,109,150 shares to be issued upon exercise of all options[11]. - The stock options are valid for a period of ten years from the grant date, expiring on October 5, 2032[7]. - No stock options were granted to directors, senior executives, or major shareholders of the company, ensuring compliance with listing rules[10]. - The remaining term of the post-IPO stock option plan is approximately 8.5 years, set to expire on October 7, 2030[11]. - The company reported that no individual was granted stock options exceeding the 1% personal limit as per listing rules[10]. - The stock options granted are part of a continuous employment contract as defined under employment regulations[10]. - The company’s stock price on the grant date was HKD 1.720 per share[7]. - The announcement does not affect other information contained in the 2021 annual report, which remains unchanged[12].
嘉和生物-B(06998) - 2022 Q3 - 季度财报